Looking Beyond COVID-19: The Future of Neurological Care

July 7th, 2021


The pandemic has led to reflection and debate across healthcare in Ireland as to how services can recover from disruption and potentially overcome some of the systemic issues that impacted our health system pre COVID-19.

Neurological care services are embracing new treatment approaches and technologies including those developed here in Ireland. On the other hand, the infrastructure to support people living with neurological conditions remains critically underfunded and underdeveloped.

Our panel discussion brings together representatives from neurology, neurorehabilitation, neuroscience research, the not for profit sector and service user perspectives on the key challenges facing neurological care and whether recovery from COVID-19 represents an opportunity to address some of the critical ch/allenges facing neurological care.

PROGRAMME: 10am to 11,30am
Opening Presentation: European Federation of Neurological Associations (EFNA) World Health Organisation Framework on Neurological Disorders

Panel Discussion: Neurological Care beyond COVID-19: A catalyst for change?
Chaired by June Shannon, Medical Journalist

Professor Orla Hardiman: National Clinical Lead for Neurology
Dr Amanda Carty: Programme Manager: Outpatient Services: National Rehabilitation Hospital
Dr Susan Coote: Chartered Physiotherapist Specialising in Neurological Rehabilitation

Gary Boyle: Patient Advocate Living with Parkinson’s Disease
Peter Murphy, Chief Executive Officer, Epilepsy Ireland
FutureNeuro: SFI Research Centre for Rare and Chronic Neurological Disorders

The webinar is targeted at a general public audience.

Click HERE to register or visit www.nai.ie for more details

Share Now:

Categories: News

1. Muscular Dystrophies

  • Becker muscular dystrophy
  • Duchenne muscular dystrophy
  • Manifesting carrier of Duchenne
  • Congenital muscular dystrophy
  •     •  General
  •     •  MDC1A (merosin-deficient congenital muscular dystrophy)
  •     •  Rigid spine syndrome (RSS)
  •     •  Ullrich congenital muscular dystrophies
  •     •  Bethlem myopathy
  • Emery-Dreifuss muscular dystrophy
  • Facioscapulohumeral muscular dystrophy
  • Limb-girdle types of muscular dystrophy (LGMD)
  •     •  General
  •     •  LGMD 1B (also known as Laminopathy)
  •     •  LGMD 1C (also known as Caveolinopathy)
  •     •  LGMD 2A (also known as Calpainopathy)
  •     •  LGMD 2B (also known as Dysferlinopathy)
  •     •  LGMD 2I
  • Ocular myopathies including ocularopharangeal muscular dystrophy

2. Myotonic Disorders

  • Congenital Myotonic Dystrophy
  • Myotonia
  • Myotonic Dystrophy

3. Congenital Myopathies

  • Central Core Myopathy
  • Congenital Fibre-type Disproportion Myopathy
  • Minicore (Multicore) myopathy
  • Myotubular or Centronuclear myopathy
  • Nemaline myopathy

4. Mitochondrial Myopathies

  • Mitochondrial Myopathies

5. Metabolic Disorders

  • Metabolic disorders (general)
  • McArdle’s Disease
  • Pompe’s Disease

6. Periodic Paralyses

  • Periodic Paralyses

7. Autoimmune Myositis

  • Polymyositis, Dermatomyositis and Sarcoid myopathy
  • Juvenile dermatomyositis
  • Inclusion body myositis

8. Spinal Muscular Atrophies

  • Severe (Type I)
  • Intermediate (Type II)
  • Mild (Type III)
  • Adult spinal muscular atrophy

9. Hereditary Motor and Sensory Neuropathies

  • (Also known as Charcot-Marie-Tooth or Peroneal muscular atrophy)

10. Disorders of the Neuromuscular Junction

  • Congenital myasthenic syndromes
  • Myasthenia Gravis

11. Friedreich’s Ataxia

  • Friedreich’s Ataxia

12. Other (Please Specify)

13. Unspecified